Lifecore Biomedical
LFCR
89 hedge funds and large institutions have $343M invested in Lifecore Biomedical in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 30 increasing their positions, 32 reducing their positions, and 8 closing their positions.
6% more capital invested
Capital invested by funds: $325M → $343M (+$18.1M)
1.73% more ownership
Funds ownership: 93.93% → 95.66% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 32
2% less funds holding
Funds holding: 91 → 89 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$5.52M |
| 2 |
ICOM
Investment Counselors of Maryland
Baltimore,
Maryland
|
+$4.95M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.07M |
| 4 |
AG
Algert Global
San Francisco,
California
|
+$902K |
| 5 |
WC
Walthausen & Co
Malta,
New York
|
+$707K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
-$2.07M |
| 2 |
NIMC
NWQ Investment Management Company
Los Angeles,
California
|
-$2.03M |
| 3 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$1.02M |
| 4 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
-$666K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$621K |
LFCR Hedge Fund Activity: Q1 2018 in Review
89 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q1 2018, worth a combined $343M — up 5.6% from $325M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of LFCR and 6 opened new positions — a net loss of 2 holders — while 32 trimmed existing stakes and 30 added.
The largest buyer was Russell Investments Group, adding an estimated $5.52M. The largest seller was Chartwell Investment Partners, cutting an estimated $2.07M.
- 89 institutional investors held Lifecore Biomedical (LFCR) as of Q1 2018, down from 91 in Q4 2017.
- Funds reported $343M of Lifecore Biomedical stock for Q1 2018, up 5.6% quarter-over-quarter.
- 6 funds opened new Lifecore Biomedical positions in Q1 2018 and 8 closed out, a net change of -2 holders.
- The largest Lifecore Biomedical buyer in Q1 2018 was Russell Investments Group, an estimated $5.52M added.
- The largest Lifecore Biomedical seller in Q1 2018 was Chartwell Investment Partners, an estimated $2.07M sold.
Based on aggregated 13F filings for Q1 2018.